Eric Haaksma News Today

Boehringer Ingelheim a global leader in animal health has received marketing authorization from the European Commission for SENVELGO active ingredient velagliflozin marking a significant step for the treatment of feline diabetes in Europe.

Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks USA - English Share this article Share this article LONDON, June 9, 2021 /PRNewswire/ -- Lifebit Biotech Ltd announces the beginning of a long-term partnership with Boehringer Ingelheim to utilise Natural Language Processing (NLP) and Artificial Intelligence (AI) for the detection and early reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sou...

Boehringer Ingelheim to detect animal diseases using AI 9 June 2021 | The captured insights can accelerate detection of the latest animal disease outbreaks Animal health firm Boehringer Ingelheim will partner with Lifebit Biotech to utilise artificial intelligence for the detection of global disease outbreaks. Technology firm Lifebit’s REAL platform automatically detects and tracks animal disease outbreaks using real-world evidence and AI. The captured insights can accelerate detection of th...